Atopic Dermatitis

Explore innovative nonsteroidal treatments for atopic dermatitis, as experts discuss personalized care strategies to enhance patient quality of life.

Explore personalized systemic therapies for atopic dermatitis, addressing patient needs, treatment options, and enhancing adherence for better outcomes.

Tina Bhutani, MD, MAS, highlights emerging topical treatments for pediatric atopic dermatitis, emphasizing improved adherence in younger children, the potential impact of ruxolitinib FDA approval for ages 2 and up, and the promise of ongoing trials in infants under 2 years.

Robert Koppel, MD, led Case-Based Roundtable attendees through 3 complex cases of atopic dermatitis that centered around available non-steroidal topicals and biologics.

Tina Bhutani, MD, MAS, discusses innovative pediatric atopic dermatitis treatments, including ruxolitinib cream, emphasizing collaborative decision-making for effective management.

Shanna Miranti, MPAS, PA-C, discusses the impact of sleep loss in pediatric atopic dermatitis and the potential of emerging therapies in young patients, such as ruxolitinib cream, to improve outcomes.

Temitayo Ogunleye, MD, guided clinicians through diverse AD cases to examine how newer agents fit into evolving treatment strategies.

Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitors (ICIs) show distinct immune profiles from classic skin conditions.

Amlitelimab shows promise in enhancing clinical outcomes and patient quality of life in atopic dermatitis, offering potential for long-term disease control.

The Japanese study found no association between cutaneous events and baseline EASI scores, eosinophil counts, or IgE levels.

In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.

At a recent Dermatology Times Case-Based Roundtable, attendees discussed several challenging AD cases.

Shanna Miranti, MPAS, PA-C, describes her clinical approach for managing moderate to severe pediatric atopic dermatitis and how she selects between the 3 available non-steroidal topicals.

Explore the INTEGUMENT-INFANT study, assessing roflumilast cream's safety and efficacy for infants with atopic dermatitis in a groundbreaking trial.

Walter Liszewski, MD, highlights the clinical impact of patch testing and shares strategies for selecting and dosing JAK inhibitors at Elevate-Derm Summer.

New survey data reveals gaps in atopic dermatitis treatment for pregnant women, highlighting the need for updated guidelines and better physician education.

Abrocitinib significantly improves lesion severity and pruritus in moderate to severe AD, offering a promising treatment option for patients.

Turn Therapeutics initiates a groundbreaking clinical trial for GX-03, the first topical IL-36 inhibitor targeting moderate to severe eczema.

An expert discusses how successful atopic dermatitis management requires patient-centered care and shared decision-making, emphasizing that treatment selection should match disease impact rather than just body surface area, with both biologics and JAK inhibitors offering safe and effective options.

An expert discusses how patient preferences, particularly needle anxiety, must be balanced with treatment effectiveness, demonstrating that oral JAK inhibitors can be excellent alternatives for patients who cannot tolerate injectable biologics.

Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

LEO Pharma reveals promising interim results for tralokinumab in treating moderate to severe atopic dermatitis on hands, enhancing patient quality of life.

Achieving optimal treatment targets and minimal disease activity significantly enhances health-related quality of life and satisfaction in patients with atopic dermatitis.

New 16-week data from the phase 2 APEX clinical trial demonstrated the anti-IL-13 antibody's efficacy across all key endpoints.